|
1
|
Kanat O and O’Neil BH: Metastatic gastric
cancer treatment: a little slow but worthy progress. Med Oncol.
30:4642013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hong Z, Chan K and Yeung HW: Simultaneous
determination of bufadienolides in the traditional Chinese medicine
preparation, liu-shen-wan, by liquid chromatography. J Pharm
Pharmacol. 44:1023–1026. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Panesar NS: Bufalin radioimmunoassays: in
search of the endogenous digitalis-like substance. J Immunoassay.
15:371–391. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kang XH, Xu ZY, Gong YB, et al: Bufalin
reverses HGF-induced resistance to EGFR-TKIs in EGFR mutant lung
cancer cells via blockage of Met/PI3k/Akt pathway and induction of
apoptosis. Evid Based Complement Alternat Med. 2013:2438592013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan S, Qu X, Xu C, et al: Down-regulation
of Cbl-b by bufalin results in up-regulation of DR4/DR5 and
sensitization of TRAIL-induced apoptosis in breast cancer cells. J
Cancer Res Clin Oncol. 138:1279–1289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang DM, Liu JS, Tang MK, et al:
Bufotalin from Venenum Bufonis inhibits growth of multidrug
resistant HepG2 cells through G2/M cell cycle arrest and apoptosis.
Eur J Pharmacol. 692:19–28. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watabe M, Ito K, Masuda Y, Nakajo S and
Nakaya K: Activation of AP-1 is required for bufalin-induced
apoptosis in human leukemia U937 cells. Oncogene. 16:779–787. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qi F, Inagaki Y, Gao B, et al: Bufalin and
cinobufagin induce apoptosis of human hepatocellular carcinoma
cells via Fas- and mitochondria-mediated pathways. Cancer Sci.
102:951–958. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsiao YP, Yu CS, Yu CC, et al: Triggering
apoptotic death of human malignant melanoma a375.s2 cells by
bufalin: involvement of caspase cascade-dependent and independent
mitochondrial signaling pathways. Evid Based Complement Alternat
Med. 2012:5912412012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang WW, Yang JS, Pai SJ, et al: Bufalin
induces G(0)/G(1) phase arrest through inhibiting the levels of
cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via
mitochondrial signaling pathway in T24 human bladder cancer cells.
Mutat Res. 732:26–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li D, Qu X, Hou K, et al: PI3K/Akt is
involved in bufalin-induced apoptosis in gastric cancer cells.
Anticancer Drugs. 20:59–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan Q and Sage EH: SPARC, a matricellular
glycoprotein with important biological functions. J Histochem
Cytochem. 47:1495–1506. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seux M, Peuget S, Montero MP, et al:
TP53INP1 decreases pancreatic cancer cell migration by regulating
SPARC expression. Oncogene. 30:3049–3061. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Azim HA Jr, Singhal S, Ignatiadis M, et
al: Association between SPARC mRNA expression, prognosis and
response to neoadjuvant chemotherapy in early breast cancer: a
pooled in-silico analysis. PLoS One. 8:e624512013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shin M, Mizokami A, Kim J, et al:
Exogenous SPARC suppresses proliferation and migration of prostate
cancer by interacting with integrin β1. Prostate. 73:1159–1170.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin J, Chen G, Liu Y, et al:
Downregulation of SPARC expression decreases gastric cancer
cellular invasion and survival. J Exp Clin Cancer Res. 29:592010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Desai N, Trieu V, Damascelli B and
Soon-Shiong P: SPARC expression correlates with tumor response to
albumin-bound paclitaxel in head and neck cancer patients. Transl
Oncol. 2:59–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Von Hoff DD, Ramanathan RK, Borad MJ, et
al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: a phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Demeure MJ, Stephan E, Sinari S, et al:
Preclinical investigation of nanoparticle albumin-bound paclitaxel
as a potential treatment for adrenocortical cancer. Ann Surg.
255:140–146. 2012. View Article : Google Scholar
|
|
20
|
Guarneri V, Dieci MV and Conte P:
Enhancing intracellular taxane delivery: current role and
perspectives of nanoparticle albumin-bound paclitaxel in the
treatment of advanced breast cancer. Expert Opin Pharmacother.
13:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen J, Shi D, Liu X, Fang S, Zhang J and
Zhao Y: Targeting SPARC by lentivirus-mediated RNA interference
inhibits cervical cancer cell growth and metastasis. BMC Cancer.
12:4642012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen J, Wang M, Xi B, et al: SPARC is a
key regulator of proliferation, apoptosis and invasion in human
ovarian cancer. PLoS One. 7:e424132012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fenouille N, Puissant A, Tichet M, et al:
SPARC functions as an anti-stress factor by inactivating p53
through Akt-mediated MDM2 phosphorylation to promote melanoma cell
survival. Oncogene. 30:4887–4900. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gorantla B, Bhoopathi P, Chetty C, et al:
Notch signaling regulates tumor-induced angiogenesis in
SPARC-overexpressed neuroblastoma. Angiogenesis. 16:85–100. 2013.
View Article : Google Scholar
|
|
25
|
Seno T, Harada H, Kohno S, Teraoka M,
Inoue A and Ohnishi T: Downregulation of SPARC expression inhibits
cell migration and invasion in malignant gliomas. Int J Oncol.
34:707–715. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horie K, Tsuchihara M and Nakatsura T:
Silencing of secreted protein acidic and rich in cysteine inhibits
the growth of human melanoma cells with G arrest induction. Cancer
Sci. 101:913–919. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sengupta S and Chattopadhyay MK: Lowry’s
method of protein estimation: Some more insights. J Pharm
Pharmacol. 45:801993. View Article : Google Scholar
|
|
28
|
Giallongo C, La Cava P, Tibullo D, et al:
SPARC expression in CML is associated to imatinib treatment and to
inhibition of leukemia cell proliferation. BMC Cancer. 13:602013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schultz CR, Golembieski WA, King DA, Brown
SL, Brodie C and Rempel SA: Inhibition of HSP27 alone or in
combination with pAKT inhibition as therapeutic approaches to
target SPARC-induced glioma cell survival. Mol Cancer. 11:202012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rahman M, Chan AP and Tai IT: A peptide of
SPARC interferes with the interaction between caspase8 and Bcl2 to
resensitize chemoresistant tumors and enhance their regression in
vivo. PLoS One. 6:e263902011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fenouille N, Robert G, Tichet M, et al:
The p53/p21Cip1/Waf1 pathway mediates the effects of SPARC on
melanoma cell cycle progression. Pigment Cell Melanoma Res.
24:219–232. 2011. View Article : Google Scholar
|
|
32
|
Jiang Y, Zhang Y, Luan J, et al: Effects
of bufalin on the proliferation of human lung cancer cells and its
molecular mechanisms of action. Cytotechnology. 62:573–583. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu Z, Sun H, Ma G, et al: Bufalin induces
lung cancer cell apoptosis via the inhibition of PI3K/Akt pathway.
Int J Mol Sci. 13:2025–2035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li H, Wang P, Gao Y, et al:
Na+/K+-ATPase α3 mediates sensitivity of
hepatocellular carcinoma cells to bufalin. Oncol Rep. 25:825–830.
2011.
|
|
35
|
Li Y, Chen L, Chan TH, et al: SPOCK1 is
regulated by CHD1L and blocks apoptosis and promotes HCC cell
invasiveness and metastasis in mice. Gastroenterology. 144:179–191.
2013. View Article : Google Scholar
|
|
36
|
Said N, Najwer I and Motamed K: Secreted
protein acidic and rich in cysteine (SPARC) inhibits
integrin-mediated adhesion and growth factor-dependent survival
signaling in ovarian cancer. Am J Pathol. 170:1054–1063. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu H, Xu Y, Chen Y, et al: RNA
interference against SPARC promotes the growth of U-87MG human
malignant glioma cells. Oncol Lett. 2:985–990. 2011.
|
|
38
|
Bhoopathi P, Gondi CS, Gujrati M, Dinh DH
and Lakka SS: SPARC mediates Src-induced disruption of actin
cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42. Cell
Signal. 23:1978–1987. 2011. View Article : Google Scholar : PubMed/NCBI
|
